A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Histologically or cytologically confirmed Stage IIIB-IVB NSCLC

- For participants who have received prior neo-adjuvant/adjuvant chemotherapy or
chemoradiotherapy with curative intent for non-metastatic disease: a treatment-free
interval of at least 6 months prior to enrollment

- Participants with any programmed death-ligand 1 (PD-L1) test result by
immunohistochemistry (IHC) are eligible for the study

- Participants without a PD-L1 test result are eligible for the study

- Measurable disease per RECIST v1.1

- Adequate hematologic and end-organ function

- Agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive methods among women of childbearing potential

Exclusion Criteria:

- Prior treatment with immunotherapy for any stage NSCLC, including early-stage
(neoadjuvant or adjuvant) disease

- Participants with epidermal growth factor receptor (EGFR) sensitizing mutations and
anaplastic lymphoma kinase (ALK) rearrangements

- Active central nervous system (CNS) metastases requiring treatment

- Spinal cord compression not definitively treated or not clinically stable

- Leptomeningeal disease

- Uncontrolled tumor-related pain

- Uncontrolled pleural, pericardial effusions, or ascites requiring recurrent drainage
procedures

- Uncontrolled or symptomatic hypercalcemia

- Malignancies other than NSCLC within 5 years prior to enrollment, except for those
curatively treated with negligible risk of metastasis or death

- Pregnant or lactating women

- History of autoimmune disease, significant pulmonary disease, or significant
cardiovascular disease

- Positive human immunodeficiency virus (HIV) or hepatitis B or C

- Active tuberculosis

- Severe infection or major surgery within 4 weeks, or oral or IV antibiotics treatment
within 2 weeks prior to enrollment

- Prior treatment with or hypersensitivity to study drug or related compounds

- Prior allogeneic bone marrow or solid organ transplant

- Administration of a live, attenuated vaccine within 4 weeks prior to enrollment

- Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the
drug (whichever is longer) prior to enrollment

- Treatment with systemic corticosteroids or other systemic immunosuppressive
medications within 2 weeks prior to enrollment